AbCellera

TetraGenetics, Inc. is a biotechnology company focused on developing therapeutic proteins and vaccines for the biopharmaceutical industry. Established in 2004 and based in Arlington, Massachusetts, the company utilizes its proprietary TetraExpress system to produce recombinant human ion channel proteins and other complex biologics. TetraGenetics specializes in the production of eukaryotic membrane and secretory proteins, which are often difficult to express using conventional systems. Among its products is IchVax, a recombinant subunit vaccine aimed at preventing white-spot disease in freshwater fish. The company is also engaged in a strategic research and development collaboration with Imbrium Therapeutics L.P., aiming to address autoimmune diseases and provide solutions for ion channel-related conditions. TetraGenetics' technology enables rapid production of properly folded, functional transmembrane proteins, positioning the company as a valuable player in the development of novel therapeutics and vaccines for both human and animal health.

Trianni, Inc. is a biotechnology company based in San Francisco, California, founded in 2010. It specializes in the development of a humanized monoclonal antibody platform that includes The Trianni Mouse, an advanced antibody discovery tool. This platform enables the isolation of monoclonal antibodies by providing a human antibody repertoire, which enhances immune responses and increases antibody diversity. By preserving the natural maturation of fully human antibodies in rodents, Trianni's technology aims to improve the speed and success rate of antibody-drug development for preventing and treating diseases. As of November 2020, Trianni operates as a subsidiary of AbCellera Biologics Inc.

Invetx, Inc. is a biotechnology company focused on developing protein-based therapeutics for animal health care and veterinary medicine. Based in Boston, Massachusetts, Invetx's team comprises veterinary scientists and clinicians dedicated to discovering and creating biotherapeutics for both pets and farm animals. The company aims to enhance health outcomes in the animal health industry by leveraging biopharma technologies, supported by a network of experts in animal and human health. Through its innovative platform, Invetx is committed to advancing a portfolio of therapies and technologies designed to improve animal care and well-being.

OrthoMab is an operator of a bispecific platform dedicated to creating improved antibody therapies. The company specializes in producing antibodies using standard production and purification techniques which are available in flexible formats that can be tailored to specific target biology and mechanisms of action.

Invetx, Inc. is a biotechnology company focused on developing protein-based therapeutics for animal health care and veterinary medicine. Based in Boston, Massachusetts, Invetx's team comprises veterinary scientists and clinicians dedicated to discovering and creating biotherapeutics for both pets and farm animals. The company aims to enhance health outcomes in the animal health industry by leveraging biopharma technologies, supported by a network of experts in animal and human health. Through its innovative platform, Invetx is committed to advancing a portfolio of therapies and technologies designed to improve animal care and well-being.

Lineage Biosciences is a biotechnology company that specialises in deep analysis of anti-body responses of human body.